Related Experiment Video
Updated: Jun 19, 2026
05:51
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
[Aripiprazole induced Parkinsonism: A case report].
S Pasquier de Franclieu1, C Germain, F Petitjean
117(e) secteur de Psychiatrie Générale, Hôpital Sainte-Anne, 1, rue Cabanis, 75014 Paris, France.
L'Encephale
|October 27, 2009
Summary
Aripiprazole, an atypical antipsychotic, can cause Parkinsonian symptoms in some patients, even at low doses. Reducing the dosage or switching medication can resolve these side effects.
Area of Science:
- Psychiatry
- Pharmacology
- Neuroscience
Background:
- Aripiprazole is an atypical antipsychotic known for its unique receptor binding profile, acting as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and an antagonist at serotonin 5-HT2 receptors.
- It is generally associated with a favorable safety and tolerability profile, including a lower incidence of extrapyramidal side effects compared to older antipsychotics.
Observation:
- A 37-year-old female patient with paranoid schizophrenia developed severe Parkinsonian symptoms, including hypertonia and akinesia, after one month of treatment with aripiprazole 10mg daily.
- These symptoms emerged despite previous treatment trials with olanzapine and risperidone, which also elicited extrapyramidal side effects.
Findings:
- The patient's Parkinsonian symptoms resolved within five days after a dose reduction of aripiprazole to 5mg per day.
- This case suggests a potential link between aripiprazole and Parkinsonian symptoms, possibly related to individual metabolic differences.
Implications:
- This case highlights the importance of monitoring for extrapyramidal symptoms, even with atypical antipsychotics like aripiprazole, particularly in patients with a history of such side effects.
- The findings suggest that genetic variations in drug metabolism, such as cytochrome P450 2D6 deficiency, might predispose individuals to developing Parkinsonian symptoms with aripiprazole.
More Related Videos
Related Concept Videos
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:11Alterations in Muscle Tone lll
Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...